Akebia Therapeutics, Inc. - 8-K Filing
Akebia Therapeutics held its annual stockholder meeting on June 17, 2026, where directors Adrian Adams, Michael Rogers, and LeAnne M. Zumwalt were elected with votes for ranging from 97.9 million to 102.4 million each. Stockholders approved an increase in authorized shares of capital stock from 375 million to 525 million and common stock from 350 million to 500 million, passing with 102.5 million votes for. Advisory non-binding votes also supported executive compensation (89.8 million for) and annual frequency for future advisory votes on pay. (Items: 5.07 Submission of Matters to a Vote of Security Holders)
Tickers: $AKBA